Vaxart Capital Surpluse from 2010 to 2024

VXRT Stock  USD 0.61  0.01  1.67%   
Vaxart Capital Surpluse yearly trend continues to be comparatively stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2024. From the period from 2010 to 2024, Vaxart Capital Surpluse quarterly data regression had r-value of  0.47 and coefficient of variation of  61.89. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
442.1 M
Current Value
459.9 M
Quarterly Volatility
122.7 M
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 M, Interest Expense of 1.4 M or Total Revenue of 7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 2.34. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Vaxart Inc over the last few years. It is Vaxart's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Vaxart Capital Surpluse Regression Statistics

Arithmetic Mean260,569,943
Geometric Mean210,057,415
Coefficient Of Variation61.89
Mean Deviation142,946,606
Median159,600,000
Standard Deviation161,272,063
Sample Variance26008.7T
Range487.6M
R-Value0.47
Mean Square Error21823.4T
R-Squared0.22
Significance0.08
Slope16,947,051
Total Sum of Squares364121.5T

Vaxart Capital Surpluse History

2024528.9 M
2023503.7 M
2022438 M
2021406.9 M
2020272.3 M
2019124.8 M
2018108.5 M

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse503.7 M528.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.